Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306155131> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4306155131 endingPage "31" @default.
- W4306155131 startingPage "31" @default.
- W4306155131 abstract "Recent advances in cancer immunology have shed light on the mechanisms that regulate the interaction of the immune system with cancer, along with the strategies of immune evasion that cancer cells employ in order to survive in the presence of anti-cancer immune responses. An accumulation of data in recent years has identified several immune checkpoint molecules, whose normal role is to down-regulate immune responses in order to maintain immune homeostasis. Expression of these molecules by cancer cells allows them to efficiently evade anti-cancer immune responses. The great potential of these findings is highlighted by the recent approval of therapeutic antibodies targeting and blocking immune checkpoint molecules. Examples include inhibitors of programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4), for the treatment of various cancers. Development of novel immunotherapies constitutes an extremely promising clinical development. The advent of CRISPR/Cas9 genome editing technologies and their application in forward genetic screens have revolutionised our ability to interrogate the cancer genome and identify genetic vulnerabilities and essentialities. With these in mind, I have carried out in vitro and in vivo CRISPR/Cas9 genome-wide forward genetic screens. These will, on one hand, enable the identification of genes whose knockouts sensitise cancer cells to the immune system. On the other hand, the screens will also allow the characterisation of novel cancer immune evasion pathways. These genes would be ideal candidates as targets of immunotherapeutic strategies. Preliminary data suggest that the targeting of antigen presentation and processing genes is lethal to colon cancer cell lines in vivo. I anticipate that these studies will aid the identification of novel therapeutic cancer targets." @default.
- W4306155131 created "2022-10-14" @default.
- W4306155131 creator A5024724352 @default.
- W4306155131 creator A5068386881 @default.
- W4306155131 creator A5079556556 @default.
- W4306155131 date "2022-10-01" @default.
- W4306155131 modified "2023-09-28" @default.
- W4306155131 title "Functional genomic studies of cancer immune evasion using in vitro and in vivo CRISPR/Cas9 genetic screens" @default.
- W4306155131 doi "https://doi.org/10.1016/j.molimm.2022.05.105" @default.
- W4306155131 hasPublicationYear "2022" @default.
- W4306155131 type Work @default.
- W4306155131 citedByCount "0" @default.
- W4306155131 crossrefType "journal-article" @default.
- W4306155131 hasAuthorship W4306155131A5024724352 @default.
- W4306155131 hasAuthorship W4306155131A5068386881 @default.
- W4306155131 hasAuthorship W4306155131A5079556556 @default.
- W4306155131 hasBestOaLocation W43061551312 @default.
- W4306155131 hasConcept C104317684 @default.
- W4306155131 hasConcept C121608353 @default.
- W4306155131 hasConcept C127716648 @default.
- W4306155131 hasConcept C144501496 @default.
- W4306155131 hasConcept C203014093 @default.
- W4306155131 hasConcept C207177822 @default.
- W4306155131 hasConcept C2777701055 @default.
- W4306155131 hasConcept C2780674031 @default.
- W4306155131 hasConcept C2780851360 @default.
- W4306155131 hasConcept C502942594 @default.
- W4306155131 hasConcept C54355233 @default.
- W4306155131 hasConcept C70721500 @default.
- W4306155131 hasConcept C86803240 @default.
- W4306155131 hasConcept C8891405 @default.
- W4306155131 hasConcept C96232424 @default.
- W4306155131 hasConcept C98108389 @default.
- W4306155131 hasConceptScore W4306155131C104317684 @default.
- W4306155131 hasConceptScore W4306155131C121608353 @default.
- W4306155131 hasConceptScore W4306155131C127716648 @default.
- W4306155131 hasConceptScore W4306155131C144501496 @default.
- W4306155131 hasConceptScore W4306155131C203014093 @default.
- W4306155131 hasConceptScore W4306155131C207177822 @default.
- W4306155131 hasConceptScore W4306155131C2777701055 @default.
- W4306155131 hasConceptScore W4306155131C2780674031 @default.
- W4306155131 hasConceptScore W4306155131C2780851360 @default.
- W4306155131 hasConceptScore W4306155131C502942594 @default.
- W4306155131 hasConceptScore W4306155131C54355233 @default.
- W4306155131 hasConceptScore W4306155131C70721500 @default.
- W4306155131 hasConceptScore W4306155131C86803240 @default.
- W4306155131 hasConceptScore W4306155131C8891405 @default.
- W4306155131 hasConceptScore W4306155131C96232424 @default.
- W4306155131 hasConceptScore W4306155131C98108389 @default.
- W4306155131 hasLocation W43061551311 @default.
- W4306155131 hasLocation W43061551312 @default.
- W4306155131 hasOpenAccess W4306155131 @default.
- W4306155131 hasPrimaryLocation W43061551311 @default.
- W4306155131 hasRelatedWork W1183554201 @default.
- W4306155131 hasRelatedWork W2810507067 @default.
- W4306155131 hasRelatedWork W2979186475 @default.
- W4306155131 hasRelatedWork W2992262155 @default.
- W4306155131 hasRelatedWork W3162164072 @default.
- W4306155131 hasRelatedWork W3217412908 @default.
- W4306155131 hasRelatedWork W4226147546 @default.
- W4306155131 hasRelatedWork W4280602468 @default.
- W4306155131 hasRelatedWork W4291367166 @default.
- W4306155131 hasRelatedWork W4306155131 @default.
- W4306155131 hasVolume "150" @default.
- W4306155131 isParatext "false" @default.
- W4306155131 isRetracted "false" @default.
- W4306155131 workType "article" @default.